Keyphrases
HIV Vaccine
100%
Vaccine Trial
100%
Placebo
100%
HIV-1 Acquisition
100%
Trial Participants
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
75%
HIV-1 Infection
50%
Unblinding
50%
Vaccination
25%
South Africa
25%
Sexually Active
25%
Dropout
25%
Treatment Group
25%
HIV Testing
25%
Caribbean
25%
Hazard Ratio
25%
Australia
25%
Preventive Vaccine
25%
Risk Behavior
25%
Gag-pol-nef
25%
STEPS Study
25%
Placebo Groups
25%
Vaccine Impact
25%
Cox Model
25%
Treatment Assignment
25%
Risk Reduction Counselling
25%
Behavior Assessment
25%
Behavior Treatment
25%
Herpes Simplex Virus 2 (HSV-2)
25%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Placebo
100%
Human Immunodeficiency Virus 1 Infection
40%
Infection
20%
HIV Test
20%
Hazard Ratio
20%
Proportional Hazards Model
20%
Human Immunodeficiency Virus Type 1 Subtype B
20%
Physical Examination
20%
Behavior Assessment
20%
Risk Reduction
20%
N (4 Methoxyphenylacetyl)dehydroalanine
20%
High Risk Behavior
20%
Behavior Therapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Placebo
83%
Human Immunodeficiency Virus 1 Infection
33%
Infection
16%
Human Immunodeficiency Virus Type 1 Subtype B
16%
N (4 Methoxyphenylacetyl)dehydroalanine
16%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus 1
100%
Human Immunodeficiency Virus
14%
Human Immunodeficiency Virus Type 1 Subtype B
14%
Risk Reduction
14%
Immunology and Microbiology
Human Immunodeficiency Virus 1
100%
Human Immunodeficiency Virus
14%
Human Immunodeficiency Virus Type 1 Subtype B
14%